Prostate cancer unveiled: AI uncovers new subtypes, paves way for tailored treatments
artificial intelligence (AI) to reveal a new form of aggressive prostate cancer which they said could help thousands of lives by revolutionising how the disease is diagnosed and treated in the future. The study, published in the journal Cell Genomics, reveals that prostate cancer, which affects one in eight men in their lifetime, includes two different subtypes termed evotypes.
The findings, led by researchers at the University of Oxford, and the University of Manchester, UK, could help provide tailored treatments to each individual patient according to a genetic test which will also be delivered using AI, they said.
«Our research demonstrates that prostate tumours evolve along multiple pathways, leading to two distinct disease types,» said lead researcher Dan Woodcock, from the University of Oxford.
«This understanding is pivotal as it allows us to classify tumours based on how the cancer evolves rather than solely on individual gene mutations or expression patterns,» Woodcock said.
The researchers worked together as part of international consortium, called The Pan Prostate Cancer Group, set up by scientists at The Institute of Cancer Research (ICR) and The University of East Anglia, UK, to analyse genetic data from thousands of prostate cancer samples across nine countries.
The team's collaboration with Cancer Research UK (CRUK) aims to develop a genetic test that, when combined with conventional staging and grading, can provide a more precise prognosis for each patient, allowing tailored treatment decisions.
